Search results
Results from the WOW.Com Content Network
Leqembi, co-developed by Biogen and its Japanese partner Eisai, had won standard approval from the U.S. Food and Drug Administration last July. It sees a potential rival in Eli Lilly's ...
Leqembi's sales are projected to grow 13-fold to 56.5 billion yen ($361.28 million) in fiscal 2024 from the year ended in March, Eisai said in its annual results on Wednesday.
GE Healthcare's potential windfall from Leqembi approval is being hampered by CMS coverage of PET scans. ... USA TODAY. 2025 Golden Globes live updates: 'Anora,' 'Wicked' jockey for best comedy ...
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [ 2 ] [ 4 ] Lecanemab is an amyloid beta -directed antibody. [ 2 ] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [ 2 ]
The British shipbuilding industry is a prime example of this with its industries suffering badly from the 1960s. In the early 1970s British yards still had the capacity to build all types and sizes of merchant ships but today they have been reduced to a small number specialising in defence contracts, luxury yachts and repair work.
The following is a list of countries by passenger and cargo ship exports. Data is for 2023, in millions of United States dollars, as reported by The Observatory of Economic Complexity and the International Trade Centre. [1] [2] Currently the top twenty countries are listed. #
Intravenous treatment of the drug, co-developed with U.S. partner Biogen, will cost about 2.98 million yen ($20,438) per patient per year, based on a Japanese health ministry panel ruling the same ...
Ships made in these yards played a key role in the discovery of America, but demand for larger ships with greater drafts meant that navy ship production was moved to Arsenal de Ferrol (A Coruña), Arsenal de Cartagena (Murcia), and La Carraca, under reforms introduced by the Marques de la Ensenada and Jorge Juan in the eighteenth century.